Neogenomics (NEO) Saham Harga
Neogenomics Harga
Selama 19 tahun terakhir pendapatan Neogenomics tumbuh 28,2% per tahun, mencapai 727,33 Juta. USD. Laba per saham tumbuh 50,4% per tahun selama 8 tahun terakhir. Bagi Neogenomics, margin bersih sebesar -14,9% turun dibanding -1,7% beberapa tahun lalu. Target harga konsensus 12 bulan untuk Neogenomics adalah 19,00 USD, sekitar di atas harga saat ini 13,1%. Dari 16 analis, 11 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Neogenomics
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Neogenomics
Pertanyaan yang sering diajukan tentang saham Neogenomics
Neogenomics Inc. (NYSE: NEO) is a leading provider of cancer-focused genetic testing services. The company's business model revolves around offering comprehensive testing solutions that aid in the diagnosis and treatment of cancer patients. Neogenomics Inc. operates through a network of laboratories and provides advanced molecular and cytogenetic testing, helping healthcare professionals make informed decisions based on genetic information. With a focus on precision medicine, Neogenomics Inc. delivers personalized treatment options, improving patient outcomes and delivering high-quality diagnostic services.
Neogenomics Inc is primarily active in the healthcare and diagnostic laboratory services industries.
The main competitors of Neogenomics Inc in the market are Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, and NeoGenomics Laboratories.
Neogenomics Inc is a leading provider of cancer-focused genetic testing services. Founded in 2001, the company is headquartered in Fort Myers, Florida. With an extensive network of laboratories across the United States, Neogenomics offers cutting-edge diagnostic and pharmaceutical services to aid in the personalized treatment and monitoring of various types of cancers. Over the years, Neogenomics has grown its portfolio of tests and services, catering to the evolving needs of healthcare professionals and patients. Their dedication to innovation and quality has positioned them as a trusted partner in the fight against cancer.
Some significant milestones achieved by Neogenomics Inc include its acquisition of Clarient Inc in 2015, which expanded its personalized medicine capabilities. The company also received full approval from the New York State Department of Health in 2017, allowing it to offer its services in all 50 states. Neogenomics Inc has strengthened its position in the molecular testing market through strategic collaborations with pharmaceutical companies. Furthermore, in 2019, the company completed its acquisition of Genoptix, enhancing its oncology diagnostics capabilities. These milestones demonstrate Neogenomics Inc's commitment to growth and innovation in the field of cancer diagnostics and personalized medicine.
Neogenomics Inc is primarily present in the United States.
Neogenomics Inc prides itself on its commitment to excellence and innovation in the field of precision medicine. With a strong corporate philosophy centered around patient care and advancing the fight against cancer, Neogenomics Inc places great importance on ethical practices and providing accurate diagnostic solutions. The company believes in fostering a collaborative environment to bring cutting-edge technologies and personalized medicine to patients globally. By constantly pushing boundaries and embracing transformative ideas, Neogenomics Inc aims to revolutionize how cancer is detected and treated. Through its dedication to quality, integrity, and patient-centric values, the company sets itself apart as a leader in the field.
Analis saat ini menetapkan target harga rata-rata 19,00 USD untuk saham Neogenomics (median: 19,00 USD), yaitu +15,2 % terhadap harga terbaru. Konsensus didasarkan pada 16 peringkat analis.
16 analis saat ini menilai saham Neogenomics: 11 merekomendasikan beli, 5 tahan, dan 0 jual. Untuk 2026, analis memperkirakan Neogenomics menghasilkan pendapatan 805,18 Juta. USD dan laba per saham 0,92 USD.
Dengan kurs saat ini, saham Neogenomics diperdagangkan pada 15,02 EUR (16,80 USD).
Saham Neogenomics (NEO) tercatat di 5 bursa, termasuk: NASDAQ (NEO), SIX (Zürich) (NG9.SW), Frankfurt (NG9.F), München (NG9.MU), Düsseldorf (NG9.DU).
Neogenomics Inc is a leading company in oncology diagnostics and offers a wide range of solutions and products to its customers. The company has been listed on the stock exchange since 2001 and is the largest provider of cancer diagnostics services in the United States. Translate the text to the best possible English.
Pendapatan diperkirakan dari Neogenomics adalah 805,18 Juta. USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Neogenomics adalah 23,72 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Neogenomics saat ini adalah 18,22. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Neogenomics.
Rasio harga-terhadap-penjualan (PSR) Neogenomics saat ini adalah 0,54. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Neogenomics.
Skor Kualitas AlleAktien untuk Neogenomics adalah 3/10.
ISIN dari Neogenomics adalah US64049M2098. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Neogenomics adalah 120159. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Neogenomics adalah NEO. Simbol ticker digunakan untuk memperdagangkan saham Neogenomics di bursa saham.
Saham Neogenomics
Kelompok Peer Neogenomics
Neogenomics Ticker
Neogenomics FIGI
Semua metrik fundamental dan analisis mendalam Neogenomics
Analisis saham kami untuk saham Neogenomics mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Neogenomics. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.